443 related articles for article (PubMed ID: 19030860)
1. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
Kumar G; Lau H; Laskin O
Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
[TBL] [Abstract][Full Text] [Related]
2. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008).
Ding Y; Jia Y; Lu C; Liu W; Yang J; Song Y; Zhu Y; Yang L; Ding L; Wen A
Biomed Pharmacother; 2012 Jun; 66(4):318-21. PubMed ID: 22397757
[TBL] [Abstract][Full Text] [Related]
3. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
4. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities.
Doehmer J; Weiss G; McGregor GP; Appel K
Toxicol In Vitro; 2011 Feb; 25(1):21-7. PubMed ID: 20828605
[TBL] [Abstract][Full Text] [Related]
5. Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes.
Ghosal A; Hapangama N; Yuan Y; Lu X; Horne D; Patrick JE; Zbaida S
Biopharm Drug Dispos; 2003 Dec; 24(9):375-84. PubMed ID: 14689466
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
[TBL] [Abstract][Full Text] [Related]
7. In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.
Chen Y; Liu L; Laille E; Kumar G; Surapaneni S
Cancer Chemother Pharmacol; 2010 Apr; 65(5):995-1000. PubMed ID: 20119716
[TBL] [Abstract][Full Text] [Related]
8. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.
Gan J; Liu-Kreyche P; Humphreys WG
Cancer Chemother Pharmacol; 2012 Jan; 69(1):51-6. PubMed ID: 21594721
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation.
Valles B; Schiller CD; Coassolo P; De Sousa G; Wyss R; Jaeck D; Viger-Chougnet A; Rahmani R
Drug Metab Dispos; 1995 Oct; 23(10):1051-7. PubMed ID: 8654192
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue.
Kuperman AV; Kalgutkar AS; Marfat A; Chambers RJ; Liston TE
Drug Metab Dispos; 2001 Nov; 29(11):1403-9. PubMed ID: 11602515
[TBL] [Abstract][Full Text] [Related]
11. Farnesol as an inhibitor and substrate for rabbit liver microsomal P450 enzymes.
Raner GM; Muir AQ; Lowry CW; Davis BA
Biochem Biophys Res Commun; 2002 Apr; 293(1):1-6. PubMed ID: 12054554
[TBL] [Abstract][Full Text] [Related]
12. Characterization of human liver cytochrome P450 enzymes involved in the metabolism of a new H+/K+-ATPase inhibitor KR-60436.
Ji HY; Lee HW; Kim HH; Choi JK; Lee HS
Toxicol Lett; 2005 Jan; 155(1):103-14. PubMed ID: 15585365
[TBL] [Abstract][Full Text] [Related]
13. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Miyashita A; Iwatsubo T; Usui T
Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
[TBL] [Abstract][Full Text] [Related]
14. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities.
Dixit V; Hariparsad N; Desai P; Unadkat JD
Biopharm Drug Dispos; 2007 Jul; 28(5):257-62. PubMed ID: 17443647
[TBL] [Abstract][Full Text] [Related]
15. The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
Yao HT; Chang YW; Lan SJ; Yeh TK
Food Chem Toxicol; 2008 Feb; 46(2):645-53. PubMed ID: 17950511
[TBL] [Abstract][Full Text] [Related]
16. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP.
Yamane M; Kawashima K; Yamaguchi K; Nagao S; Sato M; Suzuki M; Honda K; Hagita H; Kuhlmann O; Poirier A; Fowler S; Funk C; Simon S; Aso Y; Ikeda S; Ishigai M
Xenobiotica; 2015 Mar; 45(3):230-8. PubMed ID: 25350082
[TBL] [Abstract][Full Text] [Related]
17. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.
Sonesson A; Rasmussen BB
Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):195-202. PubMed ID: 21496210
[TBL] [Abstract][Full Text] [Related]
18. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Pharmacol Exp Ther; 2001 Apr; 297(1):326-37. PubMed ID: 11259560
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of liposomal curcumin cytochrome p450 metabolism.
Mach CM; Chen JH; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2010 Mar; 30(3):811-4. PubMed ID: 20393001
[TBL] [Abstract][Full Text] [Related]
20. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.
Brown HS; Wilby AJ; Alder J; Houston JB
Drug Metab Dispos; 2010 Dec; 38(12):2139-46. PubMed ID: 20847136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
